AFT Pharmaceuticals
(ASX:AFP) has successfully completed development of a faster release version of its dual action pain-killer, Maxigesic.
Maxigesic comprises two active ingredients, paracetamol and ibuprofen.
A new formulation of Maxigesic has been developed which releases one of the key components, ibuprofen, much faster in comparison with a standard Maxigesic tablet.
Additional Intellectual Property has been generated around these findings and a further patent application has also been recently filed.
The market defined by Euromonitor in 2018 for oral dose forms of analgesics for adults is close to US$4 billion.
Shares in AFT Pharmaceuticals
(ASX:AFP) last traded at $1.98.
